Table 2.

Univariate and multivariate analysis for PFS1

Variables	Univariate analysis			Multivariate analysis
	HR	P	95 % CI	HR	P	95 % CI
Age (years)
<45	1.00
45-65	1.10	0.459	0.86 -1.40
>65	1.26	0.063	0.99 – 1.62
BMI (kg/m2)
<25	1.00
≥25	0.99	0.896	0.82 – 1.19
ET naive
Yes	1.00
No	1.21	0.028	1.02 – 1.43	1.45	0.001	1.17-1.79
De novo metastatic disease
No	1.00
Yes	0.82	0.038	0.69 – 0.99
Sites
Bone only	1.00
Not visceral	1.17	0.188	0.93 – 1.48	1.26	0.132	0.93-1.71
Visceral	1.29	0.009	1.07 – 1.56	1.03	0.812	0.78-1.37
Metastatic sites score
<3 sites and ≤5 lesions	1.00
≥3 sites and ≤5 lesions/ < 3 sites and > 5 lesions	1.09	0.442	0.88 – 1.34	1.25	0.087	0.97-1.60
≥ 3 sites and >5 lesions	1.48	0.001	1.16 – 1.87	1.64	0.003	1.18-2.28
ECOG PS-first line
≤1	1.00
>1	1.60	<0.001	1.27 – 2.01	1.36	0.025	1.04-1.77
ER
≤10 %	1.00
>10 %	1.18	0.499	0.73 – 1.88
Ki-67 on primary tumor:
<14 %	1.00
≥14 %	1.37	0.002	1.13 -1.67	1.36	0.006	1.09-1.70
Endocrine responsiveness
No	1.00
Yes	0.98	0.842	0.82 – 1.18
First-line therapy
ET plus CDK 4/6 inhibitors	1.00
ET	1.77	<0.001	1.33 – 2.36	1.94	<0.001	1.37-2.73
CT	1.92	<0.001	1.42 – 2.59	1.93	<0.001	1.36-2.75